ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Glenn Baity sold 38,097 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $30.00, for a total transaction of $1,142,910.00. Following the transaction, the executive vice president now directly owns 109,253 shares of the company’s stock, valued at approximately $3,277,590. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Glenn Baity also recently made the following trade(s):

  • On Thursday, June 22nd, Glenn Baity sold 1,903 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total transaction of $57,090.00.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ ACAD) traded up 1.13% during trading on Friday, reaching $30.43. 1,204,332 shares of the company’s stock traded hands. The company’s market capitalization is $3.71 billion. ACADIA Pharmaceuticals Inc. has a 1-year low of $20.68 and a 1-year high of $40.83. The stock has a 50-day moving average of $27.92 and a 200-day moving average of $32.16.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.01. ACADIA Pharmaceuticals had a negative net margin of 948.93% and a negative return on equity of 63.07%. The company had revenue of $15.30 million during the quarter, compared to the consensus estimate of $15.17 million. During the same period in the previous year, the firm earned ($0.45) earnings per share. On average, equities analysts predict that ACADIA Pharmaceuticals Inc. will post ($2.82) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/07/22/acadia-pharmaceuticals-inc-acad-evp-glenn-baity-sells-38097-shares.html.

Large investors have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. increased its stake in ACADIA Pharmaceuticals by 23.0% in the first quarter. Envestnet Asset Management Inc. now owns 3,296 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 617 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at about $145,000. PNC Financial Services Group Inc. increased its stake in ACADIA Pharmaceuticals by 138.8% in the first quarter. PNC Financial Services Group Inc. now owns 4,384 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 2,548 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in ACADIA Pharmaceuticals by 12.8% in the first quarter. Nisa Investment Advisors LLC now owns 4,510 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 510 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new stake in ACADIA Pharmaceuticals during the first quarter valued at about $161,000. Institutional investors own 97.13% of the company’s stock.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, April 12th. HC Wainwright reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, May 10th. ValuEngine raised shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Monday, May 22nd. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the stock. ACADIA Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $42.14.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.